Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TUBB1 | Q9H4B7 | 10/20 | 0.73 |
| ▸ | TUBB4A | P04350 | 8/20 | 0.73 |
| ▸ | TUBB | P07437 | 8/20 | 0.73 |
| ▸ | TUBA3C | P0DPH7 | 8/20 | 0.73 |
| ▸ | TUBA1B | P68363 | 8/20 | 0.73 |
| ▸ | TUBA4A | P68366 | 8/20 | 0.73 |
| ▸ | TUBB4B | P68371 | 8/20 | 0.73 |
| ▸ | TUBB3 | Q13509 | 8/20 | 0.73 |
| ▸ | TUBB2A | Q13885 | 8/20 | 0.73 |
| ▸ | TUBB8 | Q3ZCM7 | 8/20 | 0.73 |
| ▸ | TUBA3E | Q6PEY2 | 8/20 | 0.73 |
| ▸ | TUBA1A | Q71U36 | 8/20 | 0.73 |
| ▸ | TUBA1C | Q9BQE3 | 8/20 | 0.73 |
| ▸ | TUBB6 | Q9BUF5 | 8/20 | 0.73 |
| ▸ | TUBB2B | Q9BVA1 | 8/20 | 0.73 |
| ▸ | TNFRSF1A | P19438 | 1/20 | 0.56 |
| ▸ | HTR1A | P08908 | 2/20 | 0.55 |
| ▸ | EGFR | P00533 | 1/20 | 0.54 |
| ▸ | CYP19A1 | P11511 | 2/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4416013 | 0.86 | TUBB1 (1.00) | TUBB1TUBB4ATUBBTUBA3CTUBA1B | |
| SCHEMBL919833 | 0.86 | TUBB1 (1.00) | TUBB1TUBB4ATUBBTUBA3CTUBA1B | |
| SCHEMBL9184995 | 0.86 | TUBB1 (1.00) | TUBB1TUBB4ATUBBTUBA3CTUBA1B | |
| Sulfamate SCHEMBL21980869 | 0.82 | TUBB1 (0.78) | TUBB1TUBB4ATUBBTUBA3CTUBA1B | |
| Sulfamate SCHEMBL21980858 | 0.82 | TUBB1 (0.78) | TUBB1TUBB4ATUBBTUBA3CTUBA1B | |
| Dimethylamine SCHEMBL9187869 | 0.81 | TUBB1 (0.89) | TUBB1TUBB4ATUBBTUBA3CTUBA1B | |
| (Z)-1,2-Diphenylethene SCHEMBL5079927 | 0.80 | HDAC1 (0.48) | CYP19A1ALDH1A1CYP1A2 | |
| (Z)-1,2-Diphenylethene SCHEMBL5079926 | 0.80 | HDAC1 (0.48) | CYP19A1ALDH1A1CYP1A2 | |
| SCHEMBL14175306 | 0.80 | CYP1A1 (0.56) | TUBB1TUBB4ATUBBTUBA3CTUBA1B | |
| SCHEMBL14175313 | 0.79 | TUBB1 (0.67) | TUBB1TUBB4ATUBBTUBA3CTUBA1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8198302-B2 | Anticancer agent having a quinone, quinone prodrug, catechol or catechol prodrug moiety; free of combretastatin A-1 | OXIGENE, INC. (US) | 2012-06-12 | — | — | US | claimed |
| EP-1601348-A4 | COMPOSITIONS AND METHODS WITH ENHANCED THERAPEUTIC ACTIVITY | OXIGENE INC (US) | 2008-12-10 | — | — | EP | claimed |
| EP-1601348-A2 | COMPOSITIONS AND METHODS WITH ENHANCED THERAPEUTIC ACTIVITY | OXIGENE, INC. (US) | 2005-12-07 | — | — | EP | claimed |
| WO-2004078126-A2 | COMPOSITIONS AND METHODS WITH ENHANCED THERAPEUTIC ACTIVITY | OXIGENE, INC. (US) | 2004-09-16 | — | — | WO | claimed |
| US-RE45907-E1 | Functionalized stilbene derivatives as improved vascular targeting agents | OXIGENE, INC. (US) | 2016-03-01 | — | — | US | disclosed |
| EP-1601348-A4 | COMPOSITIONS AND METHODS WITH ENHANCED THERAPEUTIC ACTIVITY | OXIGENE INC (US) | 2008-12-10 | — | — | EP | disclosed |
| US-7384925-B2 | 2' Hydroxy-3'-bromo-3,4,4',5-tetramethoxy-(Z)-stilbene; antimitotic agent; inhibits the assembly of tubulin into microtubules; anticarcinogenic: solid tumor cancers, neovascularization; tubulin-binding stilbenoid analogs structurally related to combretastatin A-1 and A-4 (extract from willow tree) | OXIGENE, INC. (US) | 2008-06-10 | — | — | US | disclosed |
| US-20060035868-A1 | Functionalized stilbene derivatives as improved vascular targeting agents | MATEON THERAPEUTICS, INC. | 2006-02-16 | — | — | US | disclosed |
| EP-1601348-A2 | COMPOSITIONS AND METHODS WITH ENHANCED THERAPEUTIC ACTIVITY | OXIGENE, INC. (US) | 2005-12-07 | — | — | EP | disclosed |
| WO-2004078126-A2 | COMPOSITIONS AND METHODS WITH ENHANCED THERAPEUTIC ACTIVITY | OXIGENE, INC. (US) | 2004-09-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060035868-A1 | Functionalized stilbene derivatives as improved vascular targeting agents | FLT1, FLT4, KDR | TUBB1 9/4885TUBB4A 6/4885TUBB 17/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.